Bioengineering CAR-T cells with GLP-1 and urolithin A improved their metabolic fitness and anti-tumor activity, demonstrating that peptide signaling can enhance cellular immunotherapy.
Peptide-powered T cellsGLP-1 metabolic conditioning made CAR-T cells more energetic, less exhausted, and better cancer killers
What the researchers found
GLP-1 and urolithin A metabolic reprogramming of CAR-T cells improved their energy fitness, reduced exhaustion, and enhanced anti-tumor killing activity.
Why it matters
CAR-T cell exhaustion is the biggest limitation of this life-saving cancer therapy. Using GLP-1 signaling to supercharge T cell metabolism could make CAR-T therapy more effective for more patients.
The numbers in context
Not detailed in available abstract — study focused on mechanistic pathways (mTOR, Atg4b) and functional outcomes.
How the study worked
Bioengineered CAR-T cells with GLP-1 and urolithin A metabolic conditioning. Assessed mitochondrial function, T cell exhaustion markers, and anti-tumor efficacy.
Who was studied
CAR-T cells treated ex vivo with semaglutide and urolithin A, tested in tumor models
What this study cannot tell us
Preclinical study. Clinical translation of metabolically conditioned CAR-T cells requires manufacturing process changes. Long-term effects of GLP-1 conditioning on T cells unknown.
How to read the evidence
Preliminary evidence: preclinical proof-of-concept for metabolic reprogramming of immune cells with GLP-1 signaling.
When this study was published
Published in 2025. Novel convergence of GLP-1 biology and cancer immunotherapy.
The bigger picture
This is a remarkable convergence — GLP-1 peptide biology meets cancer immunotherapy. If metabolic peptide signals can enhance immune cell fitness, it opens an entirely new dimension for both GLP-1 research and cancer treatment.
Questions still open
- Could GLP-1 drugs given to cancer patients improve their own immune cell function?
- Is GLP-1 metabolic conditioning applicable to other immune cell therapies beyond CAR-T?
- What is the optimal GLP-1 exposure protocol for T cell metabolic enhancement?
Common questions
How does GLP-1 help fight cancer?
What is CAR-T cell therapy?
Read the original research
Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity.
Cell reports. Medicine, 6(3), 102021
Citation
Akhtar, Areej; Shakir, Md; Ansari, Mohammad Sufyan; Divya; Faizan, Md Imam; Chauhan, Varnit; Singh, Aashi; Alam, Ruquaiya; Azmi, Iqbal; Sharma, Sheetal; Pracha, Mehak; Uddin, Insha Mohi; Bashir, Uzma; Shahni, Syeda Najidah; Chaudhuri, Rituparna; Albogami, Sarah; Ganguly, Rik; Sagar, Shakti; Singh, Vijay Pal; Kharya, Gaurav; Srivastava, Amit Kumar; Mabalirajan, Ulaganathan; Roy, Soumya Sinha; Rahman, Irfan; Ahmad, Tanveer. (2025). Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity.. Cell reports. Medicine, 6(3), 102021. https://doi.org/10.1016/j.xcrm.2025.102021